QUOTE AND NEWS
newratings.com  5 hrs ago  Comment 
BASEL (dpa-AFX) - Amgen Inc (AMGN) on Monday announced a neuroscience collaboration with Novartis AG (NVS) in the areas of Alzheimer's disease and migraine. The drug maker said the collaboration accelerates its potential entry...
newratings.com  6 hrs ago  Comment 
Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments Novartis International AG / Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience...
FierceBiotech  Sep 1  Comment 
Late last year, Atlas Venture joined hands with Novartis to launch gene-editing upstart Intellia and then swiftly followed up with a formal alliance to use CRISPR/Cas9 tech to fashion a new wave of therapeutics. Now, just 8 months after the pact,...
newratings.com  Sep 1  Comment 
Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma Novartis International AG / Novartis receives EU approval for Tafinlar® and Mekinist®, first combination...
FierceBiotech  Aug 31  Comment 
Bayer is pushing forward with a new heart-failure treatment that could eventually contend with Novartis' blockbuster-in-waiting Entresto, mapping out a wide Phase III program for its oral drug.
newratings.com  Aug 28  Comment 
Novartis continues commitment to go the last mile in effort to eliminate leprosy Novartis International AG / Novartis continues commitment to go the last mile in effort to eliminate leprosy . Processed and transmitted by NASDAQ OMX Corporate...
Market Intelligence Center  Aug 24  Comment 
The patented algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center found a trading opportunity with Novartis AG (NVS) that should provide a 3.22% return in just 53 days. Sell one Oct. '15 call at the $97.50 level for...
New York Times  Aug 21  Comment 
The experimental drug ofatumumab would bolster the Swiss pharmaceutical company’s portfolio of multiple sclerosis treatments.
newratings.com  Aug 20  Comment 
Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients Novartis International AG / Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma,...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki